SYNVISC® HYLAN G-F 20 | SYNVISC ONE® HYLAN G-F 20

Efficacy. Evidence. Experience.

SYNVISC® and Synvisc-One® are high molecular weight, highly cross-linked intra-articular hyaluronic acids that:[1,2]

- Mimic healthy young synovial fluid[1,2]
- Are for use in all stages of joint pathology[1,2]
- SYNVISC® is indicated to treat pain associated with osteoarthritis of the knee, hip, ankle and shoulder[1]
- Synvisc-One® is indicated to treat pain associated with osteoarthritis of the knee[2]

SYNVISC® HYLAN G-F 20 | SYNVISC ONE® HYLAN G-F 20

Important Treatment Considerations

SYNVISC® (hylan G-F 20) is an intra-articular injection used to treat pain associated with osteoarthritis of the knee, hip, ankle and shoulder. SYNVISC® contains small amounts of avian protein and should not be used in patients with related hypersensitivities. Adverse events involving the injected joint after intra-articular injections of SYNVISC® may include: transient pain and/or swelling and/or effusion. Cases of acute inflammation, characterized by joint pain, swelling, effusion and sometimes joint warmth and/or stiffness, have been reported following an intra-articular injection of SYNVISC®. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported. The post-marketing experience has identified the following systemic events to occur rarely with SYNVISC® administration: rash, hives, itching, fever, nausea, headache, dizziness, chills, muscle cramps, paresthesia, peripheral edema, malaise, respiratory difficulties, flushing, and facial swelling. If venous or lymphatic stasis is present, SYNVISC® should not be injected into the joint. SYNVISC® should not be used in infected or inflamed joints or in patients having skin diseases or infections in the area of the injection site. SYNVISC® should not be injected intravascularly, extra-articularly, or into the synovial tissues and capsule. Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronan can precipitate in their presence.[1]

Synvisc-One® (hylan G-F 20) is an intra-articular injection used to treat pain associated with osteoarthritis of the knee. Synvisc-One® contains small amounts of avian protein and should not be used in patients with related hypersensitivities. Adverse events involving the injected knee after intra-articular injections of Synvisc-One® may include: transient pain and/or swelling and/or effusion. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported. The post-marketing experience has identified the following systemic events to occur rarely with SYNVISC® administration: rash, hives, itching, fever, nausea, headache, dizziness, chills, muscle cramps, paresthesia, peripheral edema, malaise, respiratory difficulties, flushing, and facial swelling. If venous or lymphatic stasis is present, Synvisc-One® should not be injected into the knee. Synvisc-One® should not be used in infected or inflamed knees or in patients having skin diseases or infections in the area of the injection site. Synvisc-One® should not be injected intravascularly, extra-articularly, or into the synovial tissues and capsule. Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronan can precipitate in their presence.[2]

References: 1. SYNVISC® Instructions for Use, Genzyme Canada Inc., December 16, 2014. **2.** Synvisc-One® Instructions for Use, Genzyme Canada Inc., March 3, 2015.

SYNVISC® and Synvisc-One® are registered trademarks of Sanofi group.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MEMBER OF INNOVATIVE MEDICINES CANADA

sanofi

MAT-CA-2200717 V3 05/2023